outlook growth
upgrad industri view in-lin attract
pharma offer strong growth attract valuat caveat
need watch polit landscap close major
driver includ result vs expect pipelin
newsflow price develop elect outcom
growth prospect encourag see potenti upward
pressur price-to-earnings valuat expect novel diseas treatment combin
limit patent expir exposur yield healthi growth come year
estim averag compound-annual-growth-rate revenu ep us
major pharma growth estim current high-singl digit
consensu ep growth project exhibit impli potenti upward
pressur price-to-earnings multipl addit project compar ms
strategi ep compound-annual-growth-rate us major pharma price-to-earnings rel
 current mid rang histor averag
toward low end histor rang believ
market assign lower multipl due concern durabl
earn pipelin uncertainti us pricing/polit concern
pipelin prospect robust biopharma industri continu make
signific progress due better understand human biolog
technolog advanc develop effici anticip high rate
drug approv come year new drug applic step
past year approx annual
period refer exhibit mid-stag pipelin
success rate also rise exampl ceo albert bourla state
forb healthcar confer dec compani histor phase
success rate well industri averag ytd
success rate expect long term
anticip healthi us price expect manufactur
increas us list price mid-high singl digit percentag rang
experi flattish net price inflat due grow rebates/discount plu
bigger medicar part donut hole although revenu prospect
appear solid anticip us payer pressur categori me-too
altern continu challeng
sustain high us drug price remain concern
rule risk although risk signific neg action us drug price
near-term appear fade given inact date polit
percept driver watch includ potenti trump administr
action advanc medicar part intern price index demo earli
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
although investor may downplay odd implement democrat
presidenti nomine select spring moder candid would
consid posit percept candid advoc drug
price control would like neg novemb elect outcom
divid legislatur would percept posit pharma democrat
sweep would neg view section polit develop
implic us drug price percept
upgrad equal-weight overweight lilli offer strong
ep growth potenti signific pipelin option base
smallest us major pharma lowest margin pleas refer
separ report upgrad ow growth pipelin drive upsid
overweight-r us major pharma stock merck continu
anticip upward pressur merck oncolog sale ep
tabl content
event compani
revis price target base upon roll ep
polit develop implic us drug price percept
net price outlook
innov trend continu encourag
shape decis year io first-lin lung renal cancer
earli io treatment could next big thing
ibranc adjuv breast interim final readout
pneumococc readout
solanezumab phase phase readout
ozanimod ms pdufa phase uc
bcma car-t competit develop
event compani
major clinic readout
checkmat opdivo cabometyx vs sutent javelin renal
current appear best cross-trial checkmat chanc show
better result sinc cover jeff hung cabometyx
view potenti superior tki inlyta separ bavencio inlyta
discount pend final os readout given data look compar
checkmat opdivo yervoy chemo azn poseidon imfinzi
tremelizumab chemo lung cancer result implic investor percept
azn cover mark purecel report posit
top-lin oct view keytruda os result high bar unlik
match
adjuv trial melanoma bladder cancer
nsclc estim odd success adjuv
trial primarili io data metastat set approv could
potenti base upon non-surviv outcom endpoint
tirzepatid surpass phase data expect readout late
tirzepatid profil dictat abil compet novo cover mark
purcel ozemp convert trulic patient ahead trulic loe dec
tirzepatid efficaci lower weight loss safeti vomit
diarrhea profil phase difficult predict base phase data due
differ titrat schedul start dose trial length
gefapix phase chronic cough readout expect trial read
phase data show potenti efficaci reduc cough frequenc also high
rate tast disturb competitor bellu antagonist
show phase data less subject experienc tast disturb vs
gefapix phase top-lin result expect
result four dose encourag sinc announc sept
result infant three-dos prevnar infant support advanc
phase adult enter phase alreadi howev risk
decreas immunogen less efficaci serotyp includ data
surprisingli disappoint would neg impact share
palla phase adjuv earli stage breast cancer result interim efficaci
look possibl earli manag expect trial conclud late
manag caveat trial event driven possibl readout
slip earli continu assum palla succeed final
readout note success critic long-term growth given street assumpt
success
jade compar phase abrocitinib jak trial vs dupix readout atop
dermat expect differenti itch relief abrocitinib block
pathway itch dupix abrocitinib mg
show compel efficaci phase jade cross-trial dupix
result pancreat cancer pegilodecakin folfox fail show surviv
benefit compar folfox alon pancreat cancer difficult treat
nonetheless view pegilodecakin show-m lung cancer drug
alzheim catalyst expect readout high-dos solanezumab
dian-tu expect low given solanezumab previous fail larg phase
trial separ given cover matthew harrison plan aducanumab
file fda surprisingli approv drug could boost investor enthusiasm lilli
merck bristol could present earli data novel io mechan bristol
phase trial opdivo relatlimab io treatment-na melanoma
patient ifm therapeut phase sting agonist agonist
program merck state investor day extens pipelin cover
aspect tumor environ compel earli data could repres upsid
drug develop
updat data bcma-target therapi multipl myeloma throughout
saw sever earli promis data molecul differ modal
could potenti compet bristol await long-term
follow-up data addit patient understand durabl non car-t therapi
bispecif adc
opdivo yervoy chemo
pdufa rrm
pdufa low risk rs myelodysplast syndrom medalist
roch tecentriq nsclc final os readout rel pt
pdufa dlbcl
pdufa r/r multipl myeloma karmma fill expect
phase psoriasi
opdivo yervoy chemo
opdivo cisplatin erbitux radiotherapi phase adjuv cancer
opdivo yervoy chemo
opdivo yervoy chemo
opdivo yervoy chemo
long-term follow data bristol competitor bcma molecul r/r multipl myeloma
pivot trial data r/r cll
 bcma car-t r/r multipl myeloma cartitud prim compl sept
phase transfusion-depend myelofibrosi associ anemia independ plan initi
fda action ozempic/rybelsu cv indic
ptab final decis lilli ipr teva cgrp patent
phase high dose vs prev earli onset alzheim caus genet mutat dian-tu
prim compl dec ir indic readout
fda action rewind cv indic
phase data atop dermat admir prim compl feb
data high dose trial posit top-line
pdfua egfr nsclc file
phase readout gastric/gej cancer prim compl jul
potenti fda approv nsclc thyroid cancer file
phase readout chronic heart failur reduc ef emperor-reduc prim compl jun
tri-agonist phase data diabet prim/studi compl jul
basal insulin-fc weekli
novo ozemp phase combo cilofexor firsocostat nash readout prim compl jun
pdufa high dose expect file end
oral phase readout type diabet prim compl aug
phase readout chronic heart failur preserv ef emperor-preserv prim compl oct
phase readout diabet prim compl sep
phase readout diabet vs tresiba prim compl oct
phase dementia prim compl oct
phase cll/sll prim compl oct
pdufa non-radiograph axial spondyloarthr file late
pdufa type type diabet file late
phase data licens chugai primary/studi compl
data compet bimekizumab ucb phase trial vivid cosentyx comp readi sure humira comp
phase data diabet prim/studi compl dec
phase diabet
w/ nektar phase data eczema psoriasi prim/studi compl jan
outcom teva suit alleg patent infring mass district court litig stay pend resolut
ipr schedul
phase earli alzheim readout prim endpt iadr trailblazer-alz prim compl dec
phase readout diabet inadequet control lantu prim compl jan
phase readout diabet vs trulic surpass j-mono prim compl apr
phase readout diabet vs ozemp add-on metformin prim compl
phase readout diabet vs lantu prim compl may
phase earli alzheim readout prim endpt iadr prim compl aug
regulatori decis atop dermat submiss expect
phase readout diabet without sulfonylurea surpass-ap-combo prim compl feb
phase readout obes prim compl feb
phase readout nash synergy-nash prim compl
phase high dose earli alzheim readout prim compl jul studi vs
phase readout chronic kidney diseas empa-kidney pcd june
adult pediatr
keytruda chemo radiotherapi
keytruda chemo radiotherapi
roch tecentriq non-squamousnsclc final os readout rel prim compl
phase data chronic heart failur vs pbo victoria posit top-line
phase readout extens stage sclc
phase readout tnbc vs chemo prim compl dec
readout prevnar -- efficaci implic percept
keytruda phase readout cutan squam cell carcinoma prim compl dec
phase readout potenti competitor tislelizumab chemo vs chemo metastat squamou nsclc
china prim compl feb
phase readout nasopharyang cancer prim compl march
phase readout rcc vs sutent prim compl apr
phase readout bladder vs chemo prim compl may
phase readout endometriosi prim compl jun
pfe/merck kgaa phase bavencio vs dose vs chemo nsclc javelin lung
phase readout pf potenti competitor tislelizumab chemo vs chemo metastat non-squam nsclc
china prim compl sept
phase readout tyvyt innovent/lilli chemo vs chemo metastat squamou nsclc
phase readout tyvyt innovent/lilli chemo vs chemo metastat non-squam nsclc
china prim compl sept
phase imfinzi azn crt unresect stage nsclc readout prim compl sept
phase readout treatment-na hiv prim compl oct
phase tecentriq adjuv chemo stage ib-iiia nsclc readout prim compl
phase vs pneumovax adult trial readout primari studi compl aug
phase readout vs xtandi zytiga profound estimate file us eu/jpn
fda action pfizer prevnar adult file expect
phase bispecif merck kgaa/gsk vs keytruda nsclc readout prim
compl oct
phase ilari nv keytruda chemo vs keytruda metastat nsclc
merck phase vs prevnar pediatr trial pneu-link readout compl jan
phase readout stage unresect nsclc prim compl dec
keytruda phase readout msi-high vs chemo prim compl dec
solid tumor mediola readout prim compl aug
phase readout adjuv mono /neoadjuv chemo tnbc studi compl sept
dose moder sever osteoarthr us regulatori submiss earli follow eu japan
resolut mcpherson facil manufactur issu
merck adult pediatr phase readout eight trial
phase interim efficaci readout adjuv hr breast cancer palla prim compl sep
phase poc readout prelim result support studi detail releas follow compl
phase dupix jade compar atop dermat
detail data phase jade atop dermat posit top-line
phase readout non-metastat hormon sensit prostat cancer embark prim compl jul
merck phase vs pneumovax adult trial readout primari studi compl aug
competitor upadacitinib phase readout atop dermat vs dupix head pcd sept
phase vs dose vs chemo nsclc javelin lung readout prim compl jun
phase readout mainten bladder cancer javelin bladder prim compl jun
phase readout type diabet prim compl aug
phase readout alopecia prim compl sept
phase readout adjuv hr breast cancer palla prim compl sep
phase adult readout file merck
phase readout cancer pain prim compl
phase readout local advanc head neck cancer reach prim compl oct
phase readout solid tumor javelin parp medley prim compl
phase readout r/r dlbcl javelin dlbcl prim compl
phase poc readout psoriasi psoriat arthriti atop dermat
phase poc readout psoriasi
phase readout vitiligo
phase readout high risk relaps neoadjuv breast cancer penelope-b prim compl dec
fda action file expect
phase pediatr readout file merck
merck phase vs prevnar pediatr trial pneu-link readout compl jan
phase readout metastat er breast cancer patina prim compl may
phase readout head neck cancer javelin head neck prim compl apr
phase readout adjuv high-risk tripl neg breast cancer a-brav prim compl jun
phase readout ovarian vs chemo avastin javelin ovarain parp prim compl feb
potenti phase readout solid tumor combo javelin medley prim compl dec
us major pharma under-perform drug group drg index
under-perform increas vs increas exhibit
exhibit drg btk vs rel perform drg index outperform
 past year btk outperform past year
exhibit forward price-to-earnings multipl correl lt consensu growth estim project long-term ep growth impli potenti
exclud sgp beyond wye mean l-t growth averag sell-sid analyst year ep project
exhibit major pharma price-to-earnings rel current toward low end averag
present opportun
pharma price-to-earnings rel
exhibit price-to-earnings ep compound-annual-growth-rate comparison us major pharma eu major pharma
calcul price-to-earnings compound-annual-growth-rate
exhibit price-to-earnings comparison us major pharma us larg cap biotech eu pharma
growth project comp
price
price
price
thomson reuter morgan stanley research estim valuat methodolog risk associ price target referenc research report pleas contact client support follow
us/canada hong kong latin america london singapor sydney tokyo altern may
contact invest repres morgan stanley research broadway attent research manag new york ny usa
revis price target base upon roll ep
summari tabl pleas see compani risk reward page detail
invest thesi price target assumpt
stock rate price target estim compani remov consider report applic law and/or
polici may preclud issu inform respect compani time
 co llc affili co intern plc
act financi advis inc relat
propos offer acquir allergan plc allergan announc june
propos transact effect mean scheme arrang
chapter part compani act subject regulatori approv
customari close condit report inform provid herein
intend provid vote advic ii serv endors propos
transact iii result procur withhold revoc proxi
action secur holder agre pay fee
financi servic includ transact fee conting upon consumm
propos transact pleas refer note end report
polit develop implic us drug price
potenti trump administr hh action advanc price
democrat presidenti nomin spring
exhibit highest part part exposur either compani
provid ms estim
co part total revenu
co part total revenu
investor appear expect major washington action drug
price given inact date drug price rhetor appear
caus investor fatigu throughout first nine month
investor concern potenti trump
administr action legisl initi trump
administr yet take concern action partisanship
appear preclud legisl progress
percept driver watch consensu
expect adopt controversi legisl soon given
divid congress fact elect year result focus
three key percept driver potenti trump administr action advanc
medicar part intern price index demo earli although investor
may downplay odd implement democrat presidenti nomine select
spring moder candid would consid posit percept
candid advoc drug price control would like neg
novemb elect outcom divid legislatur would percept posit
pharma democrat sweep would neg view democrat control
could caus market discount higher risk govern someday negoti
directli drug price
await notic propos rulemak nprm medicar
trump administr could advanc part intern price index
demo lower price origin consid politico subscript
requir recent publish articl titl hh rework intern drug price
index rule get price lower articl indic secretari said hh plan
cut part price initi propos follow feedback presid
believ trump administr may want advanc demo
promis action drug price legisl initi face congression
nprm may get delay partli due senat financ committe
legisl prescript drug price reduct act consider final rule
would need issu may understand polit consult
propos rule may delay could affect cbo score
issu propos rule issu cbo could includ rule
financi impact baselin would caus sfc propos score
lower save understand would need issu final rule may
incom congress six-month period roll back regul enact
end presid
background medicar part price demo hh propos
medicar part via advanc notic propos rulemak anprm
octob next step notic propos rulemak nprm
would follow comment period potenti final
propos rule current pend white hous offic manag
unclear index price determin origin propos demo
aim price deriv intern price index includ mani
nation howev sinc presid trump said would issu execut
order mandat favor nation polici would pay
drug lowest price ex-u understand current law allow
presid dictat drug price
demo model origin propos complic would phase five
year administr cmmi part drug demo plan intend cover part
drug spend involv phase averag reduct price five year
initi target singl sourc drug repres part spend
would tier roll-out certain drug categori would includ year one
other subsequ ad purpos phase-in allow industri
adjust new reimburs demo model envis vendor
distributor take titl drug would pay vendor price rel
global price physician reimburs would fix fee amount unrel
price drug instead current add-on fee note intend
least make physician whole exhibit list biopharma compani within ms
coverag medicar exposur pleas see octob report propos
price chang complic detail origin part demo propos
includ potenti challeng septemb report count
led mark purcel detail intern price differ rel us
exhibit medicar exposur total revenu
global revenu
 disclos applic
net price outlook
anticip healthi us price expect manufactur increas
us list price mid-high singl digit percentag rang experi
flattish net price inflat due grow rebates/discount plu slightli bigger
medicar part donut hole result revenu prospect appear solid
said anticip us payer pressur categori me-too altern
continu challeng
medicar part donut hole bigger vs
medicar part donut hole get bigger per insur
donut hole donut hole
manufactur discount donut hole remain
increas begin
impact sale vari compani addit direct impact bigger
donut hole discount possibl patient util drug
decreas bigger donut hole lilli estim neg impact
co-pay accumul like gain traction
co-pay accumul benefit plan design shift us drug cost pharma compani
 patient discourag util program manufactur co-pay
assist longer count toward patient deduct out-of-pocket maximum
increas adopt program like increas pharma-bio industri buy-
down co-pay neg impact util juli reuter articl state
survey larg corpor employ show respond
current use co-pay accumul program anoth consid use
one articl also indic drug manufactur work
way counter program alter co-pay assist card enbrel
work fund appli patient deduct tri take
tougher stanc negoti payer
innov trend encourag
expect approv rise yoy
new drug file increas new drug approv
declin exhibit henc expect new drug approv increas
oct sinc drug applic
approv could approv approv
first action approv rate decreas exhibit
consist overal filing/approv trend notabl sinc top
two year new drug approv
exhibit fda drug approv new drug applic file figur
fda gov morgan stanley research approv data fiscal end septemb
exhibit fda drug approv new drug applic figur
fda gov morgan stanley research note fda standard review clock month prioriti
review clock moth date file sinc fda date file accept day file
approv clock date accept two month shorter date file
encourag trend number non-approv
annual decad appear lower last decad
industri need continu enhanc innov order
drive long-term revenu growth wit signific
innov specialti diseas includ cancer virolog
immune-rel disord orphan drug industri
must continu boost product yield new drug
file thu approv trend toward
precis medicin select patient popul often identifi
biomark pharma need develop increasingli
therapi drive top-lin growth
sinc industri increasingli pursu therapi special popul high
price would need gener signific sale blockbust drug
drug typic cost common medic condit
blood pressur cholesterol heartburn low-hang fruit
larg pick pharma-bio compani pursu complex diseas
smaller patient popul cancer autoimmun diseasefor exampl
approxim drug approv orphan drug
exhibit fda new drug approv sep
elbasvir grazoprevir
sofosbuvir velpatasvir
fda gov morgan stanley research approv data dec
sofosbuvir velpatasvir voxilaprevir
glecaprevir pibrentasvir
meropenem vaborbactam
merck kgaa pfizer
regeneron sanofi
regeneron sanofi
fda gov morgan stanley research approv data dec
fosnetupit palonosetron
segesteron acet ethinyl estradiol vagin system
imipenem cilastatin relebactam
fda gov morgan stanley research approv data dec
shape decis year io first-lin lung
await detail poseidon lung
look forward surviv data azn poseidon
trial note continu view keytruda result high bar
initi analys keytruda chemo show os hazard ratio hr
non-squam nsclc squamou nsclc keynote-
exhibit includ initi analys updat result
azn report posit top-lin oct oct
announc opdivo yervoy two chemo cycl show overal surviv os
benefit vs chemo four cycl interim analysi oct
azn cover mark purcel announc imfinzi chemo
combin imfinzi tremelimumab chemo combin improv progression-
free surviv vs chemo alon poseidon
main question whether ad yervoy tremelimumab
part show lung surviv result opdivo low-dos yervoy compar
cross-trial keytruda monotherapi arguabl margin wors
cross-trial furthermor opdivo yervoy trend better
opdivo monotherapi surviv howev keytruda monotherapi hr better
opdivo monotherapi hr cross-trial suggest opdivo could inferior
keytruda lung poseidon unclear azn press releas whether
tremelimumab ad benefit top imfinzi chemo
cross-trial comparison also confound poseidon chemo differ
keytruda keynot trial impact difficult
predict poseidon use four cycl chemo three month concurr imfinzi
imfinzi tremelimumab addit chemo control arm allow six cycl
chemo use two cycl chemo six week concurr opdivo
yervoy keytruda trial allow four cycl
chemo instead six chemo control arm understand standard
care four cycl chemo
nsclc
nsclc
nsclc
cross-ov
chemo io
compani present data updat analysi data wclc reach statist signific
nsclc
cross-ov chemo
io
data fda label updat analysi esmo part data esmo
exhibit keytruda opdivo nsclc result
tc ic
nsclc
tc ic
cross-ov chemo io
tc tumour cell ic tumour-infiltr immun cell express central evalu ventana assay tc ic tc ic
compani present os data updat analysi wclc data updat analysi
look forward javelin renal
keytruda inlyta current appear best rcc cross-trial rcc os
hazard ratio hr keytruda inlyta opdivo
yervoy bavencio inlyta javelin renal
tecentriq avastin immot intermediatepoor risk os hr
keytruda intermedi poor opdivo yervoy bavencio
succeed interim os still matur exhibit
toxic profil difficult compar cross-trial opdivo yervoy combo appear
best base grade trae bavencio inlyta lowest discontinu due
trae treatment-rel advers event trae grade opdivo yervoy vs
sutent vs bavencio inlyta vs sutent vs grade
trae keytruda inlyta vs sutent vs opdivo yervoy vs sutent
vs bavencio inlyta vs sutent vs trae lead
discontinu keytruda inlyta vs sutent vs opdivo yervoy vs
sutent vs bavencio inlyta vs sutent vs
bavencio inlyta look compar keytruda inlyta overal
subgroup bavencio count pend final javelin renal os
readout notabl favor risk patient bavencio hr consider
better keytruda hr would also highlight
month surviv rate keytruda bavencio appear roughli compar
approxim differ os benefit arguabl may driven
sutent arm surviv rate compar roughli
javelin renal last least k-m os curv indic
littl data censor month appear still
consider data censor month javelin renal mean os
curv month javelin renal could still chang significantli merck
kgaa cover joseph lockey
bristol trial chanc show better result keytruda cm-
compar opdivo cabometyx sutent cabometyx view
potenti superior tki inlyta cover jeff hung
exhibit rcc cross-trial comp trial use sutent activ compar
safeti patient treat
trae lead discontinu
nr reach indic n/a
exhibit kaplan-mei plot overal surviv
exhibit javelin renal kaplan-mei plot overal surviv
earli io treatment could next big thing
wave major io opportun adjuv set neoadjuv therapi
given primari treatment usual surgeri limit durat adjuv
therapi given primari treatment usual surgeri typic long
durat repres major opportun estim three biggest
cancer potenti breast cancer nsclc non-smal cell lung cancer
head neck cancer imposs time predict likelihood success
trial potenti interim readout current includ futur
adjuv indic model success would yield
upsid project
estim potenti us alon would drive materi upsid
estim success assumpt uncertain trial succeed
exist io sale metastat cancer would cannib base upon
seer region stage patient number estim top three cancer opportun
breast cancer subdivid triple-
neg nsclc cancer next two renal
liver howev high confid estim given lack
data signific uncertainti assumpt regard patient number
penetr treatment durat cost comparison three biggest cancer
impli patient estim provid compani ir breast non-smal cell lung
renal annual opportun us alon could impli sale potenti
global exhibit exhibit
exhibit us adjuv annual sale potenti estim number new cancer case
us new case
compani trial
estim annual adjuv sale potenti take region stage number assum penetr treatment one year use drug list price use nci seer data region stage cancer
neo adjuv patient number would like gross approxim actual patient popul comparison obtain potenti address patient popul estim compani
vari dramat case exhibit assum penetr rate cancer figur could significantli higher lower depend indic efficaci result use list price
found close medicar part asp low singl digit differ howev compani could offer discount adjuv treatment due longer treatment durat assum one year treatment
figur could higher lower depend upon indic efficaci result
seer us nation cancer institut surveil epidemiolog end result seer program publish cancer statist
region stage cancer spread nearbi lymph node tissu organ
distant stage cancer spread distant part bodyi metastat
seer morgan stanley research compani report
exhibit seer region stage case vs compani provid adjuv patient estim provid seer distant stage metastat case
seer morgan stanley research compani report
could see updat eight adjuv trial azn
updat bristol includ intent-to-treat popul recurrence-fre surviv rf
data adjuv melanoma disease-fre surviv data
adjuv muscle-invas bladder cancer mibc patholog
complet respons pcr data neoadjuv nsclc bristol
previous announc reach statist signific
co-primari endpoint rf melanoma patient continu assess
co-primari endpoint rf intent-to-treat popul statu
updat roch includ regulatori fill adjuv mibc
neoadjuv triple-neg breast cancer tnbc data
adjuv nsclc updat azn includ progression-fre surviv
object respons rate orr data major patholog
respons mpr data aegean exhibit asid merck
adjuv tnbc posit readout sept see discuss
azn cover mark purcel
exhibit neo/adjuv trial readout expect accord ct gov and/or compani present
ef event-fre surviv length time primari treatment cancer end patient remain free certain complic event treatment intend prevent delay
disease-fre surviv rf recurrence-fre surviv length time primari treatment cancer end patient surviv without sign symptom cancer
progression-fre surviv length time treatment diseas cancer patient live diseas get wors
os overal surviv length time either date diagnosi start treatment diseas cancer patient diagnos diseas still aliv
pcr patholog complet respons lack sign cancer tissu sampl remov surgeri biopsi treatment radiat chemotherapi
mpr major patholog respons predefin percentag less residu viabl tumor primari tumor
morgan stanley research compani report
estim odd success adjuv trial primarili
io data metastat set opdivo keytruda approv
adjuv melanoma surgeri azn imfinzi approv stage nsclc
concurr chemoradi ccrt success would necessarili
serv read-through cancer compar endpoint metastat
set differ adjuv set exampl tnbc
keytruda monotherapi recent fail improv overal surviv primari endpoint vs
chemo metastat tnbc neoadjuv keytruda chemo
follow adjuv keytruda monotherapi met primari endpoint patholog
complet respons pcr vs neoadjuv chemo local advanc tnbc keynote-
data current matur enough show result event-
free surviv ef co-primari endpoint overal surviv os secondari endpoint
adjuv treatment
howev approv neo/adjuv set could base non-o endpoint
pcr fda previous provid guidanc use pcr endpoint
support acceler approv neoadjuv treatment high-risk early-stag
breast cancer roch perjeta pertuzumab grant acceler approv
breast cancer neoadjuv treatment base pcr data grant
regular approv adjuv treatment base invas disease-fre surviv
idf data asid merck plan share earli interim analysi data pcr
regulatori author
know mrk- bmy-sponsor phase neo adjuv trial across
indic current run trial indic except breast
cancer repres us annual sale potenti trial across six
indic repres annual us sale potenti ten trial
neoadjuv adjuv treatment adjuv treatment typic
year exhibit trial may read earli interim analys trial
neoadjuv compon could report patholog respons data well ahead
exhibit adjuv trial order potenti readout primari complet date
morgan stanley research compani report
breast cancer current compani run trial
breast potenti largest indic estim
estim efs/o readout assum could interim
readout much earlier roch compani run trial
ef /dfs/o readout primari
complet date apr pcr run two tnbc trial includ
posit pcr readout sept roch run three tnbc
trial includ expect pcr data regulatori
submiss exhibit
nsclc azn current run total trial
run four trial expect pcr data
three trial primari complet date
run two trial primari complet date
azn seven trial primari complet date
 cancer two trial adjuv neoadjuv keynote-
company-sponsor trial current
knowledg potenti readout respect exhibit
success like crucial
theoret blockbust potentialor otezla global sale
run rate current despit modest efficaci otezla approv global
sale yoy growth exhibit show otezla efficaci
consider less xeljanz taltz remind bristol/celgen
divest otezla cover matthew harrison due concern
rais ftc regard merger
phase trial expect complet juli registr trial poetyk-
current enrol expect
complet date juli understand expect data
earli trial includ otezla activ compar
understand disclos dose competit reason
phase efficaci look highli encourag efficaci result highli compel
compar cross-trial oral otezla doubl respond rate
addit cross-trial efficaci result appear fall bit short newer inject il-
especi exhibit includ respond rate
mg qod mg qd dose significantli lower
obviou concern safeti signal observ phase seriou advers
event sae observ two highest dose mg bid mg qd
patient arm includ placebo three
highest dose arm drug-rel mg bid mg bid
mg qd compar placebo discontinu due vs
respect frequent nasopharyng headach diarrhea
nausea upper respiratori tract infect
potenti competitor dual phase
psoriasi ibd ulcer coliti crohn diseas complet phase
trial psoriasi march comment phase phase show
chang pasi score week seven arm dose vs
placebo respond rate rang vs phase trial
ulcer coliti primari complet dec phase trial crohn
diseas primari complet nov phase trial vitiligo primari
complet dec three trial also evalu pf-
phase alopecia primari complet
expect sept
exhibit cross-trial comparison plaqu psoriasi oral data week oral otezla data week oral xeljanz week
inj taltz data week note pfizer abandon xeljanz psoriasi awar jak develop
opt pivot
exhibit summari phase safeti
mirikizumab would late entrant crowd psoriasi market ibd
success could critic
mirikizumab face crowd competit landscap still see signific sale
potenti mirikizumab late market psoriasi earli market
inflammatori bowel diseas possibl mirikizumab could first
approv ulcer coliti
mirikizumab phase psoriasi trial could read
expect primari complet date march march includ
nv consentyx activ compar head-to-head addit placebo
sever alreadi approv psoriasi stelara
approv plaqu psoriasi psoriat arthriti crohn diseas tremfya
sun ilumya approv plaqu psoriasi
psoriasi market also crowd mechan includ three
approv plaqu psoriasislilli taltz novarti cosentyx
valeant bauch siliq addit ucb announc posit toplin
bimekizumab phase trialsb vivid readi surein late includ
show superior cosentyx expect data present
mirikizumab develop inflammatori bowel diseas ibd offer greater
potenti psoriasi view phase ulcer coliti trial
induct expect primari complet sept mainten
expect primari complet jun lilli report posit ulcer coliti phase
data june separ phase crohn diseas trial expect
primari complet feb lilli report posit crohn phase data may
believ could signific upsid sale estim current
assum launch sale
could first-in-class treat hair loss phase alopecia trial
primari complet expect sept trial enrol
patient alopecia areata scalp hair loss primari endpoint
percentag patient achiev absolut sever alopecia tool score
week final complet expect march
phase show placebo-adjust mean improv sever
alopecia tool score addit patient show improv
show improv show improv
seriou advers event discontinu due common
infect gi disord skin sq tissu disord mild
data support fda grant breakthrough therapi design sept
phase readout indic ahead phase trial ulcer coliti
primari complet dec phase trial crohn diseas primari
complet nov phase trial vitiligo primari complet dec
three trial also evalu
addendum develop alopecia even though show
better efficaci phase mean improv also show wors side
expect differenti itch relief
look forward head-to-head trial readout vs dupix abrocitinib
jade compar trial compar abrocitinib jak vs sanofi regeneron
dupix mab patient moderatesever atop dermat
background topic therapi primari endpoint investig global assess
iga eczema area sever index easi week estim
primari complet dec final complet feb sanofi cover
mark purcel regeneron cover matthew harrison
abrocitinib mg show compel efficaci phase cross-trial dupix
compar placebo-adjust result jade cross-trial dupix phase
trial easi abrocitinib mg
vs dupix easi vs iga respons
vs pruritu nr improv
vs abrocitinib result week dupix result
hope show faster better itch relief vs dupix key
differenti abrocitinib block pathway itch
dupix jade compar power show superior key secondari
endpoint reduct itch scale
 head appear excit jade compar call mikael dolsten
said excit studi conclud potenti file materi
includ aggreg safeti data head-to-head dupix felt
import trial sens expect drug show toler
safeti favor expect abrocitinib base current histor comparison
well efficaci clearanc skin specif endpoint
itch relief pruritu reduct one critic patient-friendli center
endpoint expect believ abrocitinib would outperform dupix
clinic meaning manner strong fast onset data avail
although head-to-head show class perform better
clinic far head-to-head reason want document
hypothesi also scienc behind inhibit major
itch mediat cover dupix
abrocitinib safeti issu includ rate nausea median durat
day decreas platelet count hemorrhag event mg dose
seriou advers event sae abrocitinib mg mg vs
placebo discontinu due abrocitinib mg mg vs
placebo platelet count reach nadir week trend toward baselin
data provid one patient dose discontinu due low platelet
count rate nausea abrocitinib abrocitinib mg
placebo median durat nausea ci day
mg group day mg group case
expect similar result abrocitinib second phase trial jade
posit top-lin announc sept data could
present
posit top-line result announc leo pharma tralokinumab mab
three phase studi detail disclos accord press
releas tralokinumab met primari secondari endpoint three pivot
trial ecztra ecztra ecztra adult moderate-to-sever atop
dermat leo pharma cover plan submit applic regulatori
approv share detail result
exhibit atop dermat cross-trial comparison placebo-adjust efficaci result
mean chang easi
iga
atop derm ph candid show-
given readout date
expect low given checker past mechan
mab atop dermat trial expect complet may
primari efficaci outcom iga least improv
competitor etokimab fail atop dermat phase recent
nov cover announc anitbodi etokimab
fail phase atla trial four dose miss primari endpoint chang
easi score vs placebo week
furthermor sanofi regeneron phase trial suggest may inferior
dupix least asthma sanofi june press releas state
dupix monotherapi numer better across
endpoint phase asthma trial although trial power show
differ combin dupix show increas benefit vs
dupix monotherapi either howev compani still evalu
atop dermat phase monotherapi combin dupix
background cytokin part famili alarmin
exhibit cytokin alarmin
releas epitheli cell expos
molecul recogn immun system danger signal believ play
import role allergi highli express skin atop dermat patient
activ diseas
ibranc adjuv breast interim final readout
palla expect late penelope-b shortli
project ibranc grow includ
approxim adjuv ibranc approv metastat breast cancer
conduct two phase adjuv post surgeri outcom trialspalla
penelope-bto broaden indic earli stage breast cancer current
model global ibranc sale increment early-
stage breast cancer plu exist indic ex-u growth yield
consensu approxim ibranc could captur vast major
market share earli stage breast cancer rel clean safeti profil
rel competitor
interim efficaci look palla expect earli
manag expect trial conclud late howev trial event
driven possibl readout slip earli second interim analysi
take place total event occur expect four
year first patient random studi plan origin plan
patient enrol base sampl size calcul made
amend protocol increas enrol size current actual enrol
due slower anticip event rate
expect palla succeed final readout breast cancer expert host
physician panel day januari state believ palla
penelope-b sized/design appropri succeed
could also final idf primari endpoint readout penelope-b
end earli understand two interim analys
final idf analysi expect
clinicaltri gov updat indic expect primari complet decemb
competitor drug side effect issu could limit uptak adjuv
breast see limit competit threat ibranc early-stag breast cancer given
side effect issu early-stag patient may toler novarti kisqali carri
cardiovascular risk lilli verzenio carri diarrhea risk
trial first adjuv breast trial read follow lilli
novarti trial clinicaltri gov indic palla primari final complet
sept sept penelope-b primari final complet dec
nov lilli verzenio phase monarch trial high risk stage
adjuv breast cancer primari final complet date april june
novarti cover mark purcel kisqali phase natale trial earli
stage adjuv breast cancer primari final complet date
background phase adjuv surgeri outcom trial palla
penelope-b palla compar ibranc two year standard endocrin
therapi vs standard endocrin therapi patient earli stage
stage breast cancer primari endpoint invas diseas free surviv
idf treatment durat least five year palla estim
primari final complet sept sept penelope-b compar
ibranc month standard anti-hormon therapi vs standard anti-hormon
therapi patient earli stage breast cancer high-risk
relaps neoadjuv chemotherapi surgeri henc think repres
smaller opportun palla primari endpoint idf estim primari
final complet decemb novemb
palla statist design final event studi power detect
hr base adjuv trial ecog doxorubicin cyclophosphamid
paclitaxel avastin simul anticip idf rate
ibranc endocrin therapi vs endocrin therapi absolut
differ interim efficaci analys plan
event occur first interim safeti futil pass
sometim second interim superior futil safeti expect
penelope-b statist design final event studi power
detect hr p-valu interim efficaci analys plan
event occur nomin -level
expect interim safeti futil interim
overwhelm efficaci futil safeti final interim analys
expect final idf interim os analysi expect
final os analysi expect clinicaltri gov updat
indic expect primari complet decemb studi complet
pneumococc readout
prevnar phase infant phase adult readout
await infant poc data adult phase
prevnar largest franchis sale next-gen develop
success key futur growth prospect current sell valent vaccin
seek upgrad cover diseas serotyp merck race
narrow valent vaccin candid call
look forward readout prevnar phase infant trial
phase adult trial issu press releas sept announc
preliminari result three dose prevnar infant support advanc
phase pr spars detail indic overal safeti profil
similar prevnar immun respons serotyp induc
infant detail releas follow complet four dose separ
pr indic three phase adult trial
complet enrol file remain track
mean could month behind merck phase adult trial
pneu-flu pneu-path expect conclud june decemb
exhibit battl pneumococc vaccin
present
earli
infant trial take longer adult trial infant receiv four dose adult receiv one
expect infant phase proof-of-concept result four dose
encourag infant poc trial includ arm hope
efficaci share serotyp safeti profil roughli similar
anticip success given core pneumococc conjug vaccin
expertis adult enter phase alreadi howev risk
decreas immunogen less efficaci serotyp includ data
surprisingli disappoint would neg impact share
infant appear roughli year behind merck infant time
start phase infant trial earli could approxim year behind
merck infant trial start dec june complet expect
jan dec respect
case poc data disappoint develop back-up pf-
phase could use also plan
offer dose given separ current
valent vaccin phase trial three prevnar administ
togeth prevnar follow one month later
singl dose complet date june
breadth coverag like drive adopt view merck cover two
serotyp howev follow-on
cover five serotyp merck success launch
short time would unlik impact sale long
merck phase data suggest higher serotyp immun respons prevnar
may necessarili translat better protect clinic outcom merck
shown compar immun reaction head-to-head vs prevnar
share serotyp except serotyp show higher immun
reaction accord acip slide serotyp caus remain prevnar-
type diseas burden us countri use prevnar howev believ
fda cdc would give claim better outcom base
exhibit merck show higher immun reaction prevnar serotyp
potenti greater adult coverag
merck initi phase trial pneumococc vaccin adult
would potenti offer greater coverag merck disclos
serotyp mani serotyp cover except vaccin expect
cover market phase trial expect start dec
primari studi complet expect august
exhibit pneumococc vaccin adult
model sale pegilodecakin pegyl armo vs
consensu oct lilli report phase sequoia trial fail show
surviv benefit studi compar pegilodecakin folfox vs folfox
pancreat cancer pancreat cancer difficult treat nonetheless view
pegilodecakin show-m lung cancer well
pegilodecakin two combo lung cancer trial trial evalu
keytruda pegilodecakin vs keytruda monotherapi nsclc primari
endpoint orr secondari endpoint includ os estim complet
date nov primari may secondari lilli state
earn call readout expect trial evalu opdivo
pegilodecakin vs opdivo monotherapi nsclc primari endpoint orr
secondari endpoint includ os estim complet date aug
primari aug secondari lilli ir state result in-hous
would present
lilli acquir armo may time purchas price
lilli market cap repres premium previou day close stock
model sale gefapix antagonist vs consensu
merck believ gefapix could pipelin product potenti
opportun chronic cough endometrial-rel pain sleep apnea sensori
function diseas view opportun interest look forward
valid given novel mechan seen phase data chronic
cough addit product observ alter tast phase chronic
cough trial see
two phase chronic cough trial readout expect
trial evalu gefapix mg mg vs placebo primari
endpoint cough per hour week expect primari final complet
juli assum readout trial evalu gefapix
mg mg vs placebo primari endpoint cough per hour week
expect primari final complet jan assum readout
phase trial show potenti efficaci chronic cough phase trial patient
show cough frequenc reduc placebo-adjust week cough per
hour decreas gefapix vs placebo dose
test mg twice day phase trial patient show decreas least
squar mean awak cough frequenc week mg twice day dose
trend improv mg mg dose exhibit exhibit
gefapix commerci potenti could impact high rate tast
disturb phase trial patient report tast disturb
six patient drop phase trial rate dysgeusia tast distort
metal tast mg mg mg vs
placebo rate hypogeusia decreas tast mg mg
mg vs placebo rate ageusia complet lack tast
mg mg mg vs placebo total rate
alter tast sensat unclear may overlap exhibit
exhibit gefapix advers event tast disturb dysgeusia alter tast hypogeusia
decreas tast ageusia complet lack tast
bellu health antagonist could pose signific threat
gefapix given low rate tast alter potenti compar efficaci
bellu cover believ high select vs receptor
differenti compar antagonist includ merck gefapix
maintain tast function due lower inhibit exhibit exhibit
phase studi show subject experienc tast alter
none experienc ageusia pre-clin anim model gefapix
appear similar efficaci exhibit exhibit bellu current
conduct phase relief chronic cough top-lin result anticip mid-
bayer recent complet phase studi
antagonist chronic cough like advanc program phase
trial shionogi recent complet phase japan studi antagonist
chronic cough look initi phase global studi earli shionogi
cover shinichiro muraoka bayer cover joseph lockey
exhibit inhibit link efficaci inhibit link tast effect
exhibit competit landscap chronic cough
exhibit phase studi show low incid tast
disturb predict therapeut dose
exhibit pre-clin studi efficaci comparison
gefapix
tirzepatid gip/glp phase high dose trulic glp
tirzepatid design offer greater hbalc control weight loss cardiovascular
benefit lilli current drug trulic tirzepatid deliv compel phase
result could significantli blunt risk gener trulic decemb dec
lilli announc plan conduct head-to-head cardiovascular outcom trial
phase surpass program data expect read start late
tirzepatid profil includ month dose titrat dictat commerci
potenti abil compet novo ozemp convert trulic patient
ahead trulic loe dec monotherapi vs placebo
monotherapi vs novo tresiba expect primari complet date
sept oct
gip add efficaci also gi side effect tirzepatid gip/glp shown strong
control greater weight loss novo ozemp glp cross-trial also higher
rate vomit diarrhea phase week tirzepatid highest dose mg
show reduct placebo-adjust vs ozemp high dose mg
week key advantag initi data weight loss
pound pound placebo-adjust vs ozemp pound pound data
phase dose titrat studi ada indic vomit diarrhea
rate week similar previously-pres result week
although lilli explain sever less titrat schedul henc
drop-out rate due advers event lower vs previous ozemp
show vomit diarrhea rate week novo cover mark
tirzepatid phase efficaci profil robust detail difficult
predict tirzepatid lower especi weight loss phase difficult
predict base phase data week week durat
titrat much slower exhibit durat endpoint includ
dose escal period week mg unclear much weight loss
attribut gi side effect phase trial consider longer
five surpass trial current clinicaltri gov four week one
week mg treatment period week week respect
trial test mg mg mg dose patient random one
tirzepatid arm control/placebo arm one achiev
target dose remain rest trial
vomit diarrhea rate sever also tbd phase tirzepatid titrat four
mg mg week mg vs four eight week inject oral
semaglutid lilli seek maxim efficaci minim side effect slow dose
escal gi side effect may mechanist gip gastric inhibitori polypeptid
made cell upper small intestin phase slower titrat schedul
unvalid remain seen degre slower titrat lessen vomit
diarrhea rate sever patient titrat mg week phase
phase titrat follow mg everi four week mg dose achiev
four week mg dose achiev week mg achiev week novo
inject ozemp mg dose requir eight week mg four week mg
four week oral semaglutid mg dose requir eight week mg four
week mg four week
extend titrat schedul could commerci issu seamless
patient perspect everi patient need maximum dose
tirzepatid mg dose expect yield best control weight loss
titrat five month could view oner physician particularli
largest prescrib group primari care doctor said adjust
requir patient simpli receiv pen devic higher
dosag titrat lastli patient like requir titrat
highest dose
trulic high dose make competit novo ozemp
look forward data posit top-line announc june
june lilli announc trulic mg show superior
lower weight reduct vs trulic mg week importantli safeti
toler profil higher dose consist known profil
trulic mg trial expect complet late evalu long-term
ozemp current view efficaci trulic approv dose
week trulic mg monotherapi lower baselin placebo
weight kg week ozemp mg monotherapi lower
baselin placebo-adjust weight kg kg placebo-adjust
solanezumab phase phase readout
lilli alzheim dementia portfolio appear well posit benefit
alzheim therapi progress lilli portfolio candid dementia
pipelin view well posit benefit alzheim
therapi progress especi wake fill alzheim candid
aducanumab fda surprisingli approv drug would boost investor enthusiasm
lilli alzheim portfolio view lilli upcom two readout
solanezumab high risk-high reward
solanezumab alreadi fail phase anoth chanc
dian trial
view dian-tu readout wildcard solanezumab phase dian-tu
trial compar solanezumab roch gantenerumab individu
alzheim disease-caus genet mutat autosom domin ad trial
small number patient primari endpoint chang dian-tu
cognit composit score use trial posit differ
rel prior trial includ higher dose mg vs mg longer
treatment durat four year vs month lilli ir told us set read
earlier ct gov primari complet date decemb reflect
origin plan includ bace inhibitor atabecestat atabecestat arm
stop roch cover mark purcel cover david lewi
given adad popul small manag could extrapol find
inform studi target broader popul larger commerci opportun lilli
conduct phase presymptomat alzheim diseas trial subject
amyloid plagu dementia cognit impair yet trial
estim enrol patient primari complet date juli
novel unvalid mechan
phase trial lewi bodi dementia expect complet june
presenc compar dopamin receptor posit alloster
modul vs placebo patient lewi bodi dementia lbd primari
endpoint chang baselin week continu attent coa
composit score cognit drug research computer cognit batteri cdr-
mechan unvalid lewi bodi dementia lbd consist two clinic diagnos
parkinson diseas dementia dementia lewi bodi lbd associ
abnorm deposit alpha-synuclein protein brain call lewi bodi
deplet neurotransmitt dopamin howev unclear lbd
treat dopamin agonist dopamin pam pam ligand bind
differ site receptor agonist amplifi receptor respons
endogen agonist releas
lbd estim affect million patient us much bigger
opportun would alzheim believ second common
dementia behind alzheim estim affect million peopl us
mani million global
phase anchor-crc trial expect read single-arm trial enrol
patient braf colorect cancer evalu braftovi braf mektovi mek
erbitux kra primari endpoint orr secondari endpoint includ os
primari complet date june final complet expect oct
result challeng assess without control arm hope orr
least braf associ poorer prognosi crystal trial
treatment folfiri erbitux braf subgroup show orr median
month median os month comparison braf-wt
subgroup show orr median month median os
braftovi mektovi combo could approv braf
reduct risk death vs chemo folfiri irinotecan erbitux control median
os month vs month overal respons rate vs file
expect
gain braftovi mektovi part array acquisit june
purchas price previou day close use cash debt
state deal expect dilut neutral
accret start
ozanimod ms pdufa phase uc
multipl sclerosi ms crowd market
see ozanimod me-too admittedli better cardiac safeti multipl
sclerosi ozanimod sphingosin agonist
believ caus lymphocyt sequestr lymph node presum
reduc migrat central nervou system drug gilenya
mayzent current sold novarti novarti cover mark purcel
estim sale expect ozanimod receiv fda approv given
panel expect fda approv novarti gilenya mayzent
mechan howev also believ ozanimod receiv gilenya-lik
class label requir first-dos monitor management project peak sale
pdufa date relaps form ms march ema decis
relapsing-remit multipl sclerosi rrm expect
expect label similar gilenya rrm competit landscap fairli
crowd base phase radianc sunbeam trial data ozanimod similar
efficaci gilenya exhibit lower incid class side effect
cardiac liver compar gilenyather report case
symptomat bradycardia degre heart block nonetheless expect ozanimod
requir first dose monitor like gilenya furthermor competit
intensifi significantli recent approv novarti mayzent siponimod
merck kgaa mavenclad oral cladribin well potenti entri gener gilenya
novel moa ibd moa may better
inflammatori bowel diseas ibd repres signific opportun phase
data uninspir novel mechan may prove better manag
state ozanimod could first-in-class drug howev expect
ibd competit landscap becom increasingli crowd novel mechan
develop includ arena etrasimod oral gilead filgotinib jak oral
lilli mirikizumab inj exhibit gilead cover matthew harrison
arena cover
exhibit pipelin drug crohn diseas cd ulcer coliti uc
modest expect ozanimod ibd phase touchston studi
ulcer coliti uc ozanimod vs placebo achiev clinic remiss rate
vs compar cross-trial phase trial result simponi vs
takeda entyvio vs appear wors etrasimod vs
cross-trial comparison challenging induct period readout
differ wk etrasimod vs wk ozanimod regard safeti
think ozanimid etrasimod compar low seriou advers
event advers cardiac event exhibit exhibit ozanimod phase
north trial expect readout mid arena advanc phase
uc trial still recruit primari complet date crohn
diseas ozanimod phase yellowston primari complet expect feb
final complet apr arena plan initi phase
asid bristol/celgen previous discontinu phase trial crohn diseas
differ molecul mongersen oral antisens
oligonucleotid cover david lewi takeda cover shinichiro
exhibit oral agent efficaci safeti data comparison uc ozanimod vs arena
moder sever uc
reduct mayo clinic score
etrasimod data ozanimod data nejm
exhibit clinic remiss rate approv biolog uc
note head-to-head studi comparison
bcma car-t competit
promis earli data clear leader among bcma-target
therapi multipl myeloma
bcma hot new target multipl myeloma competit like fierc
least bcma target agent develop current ide-cel
develop partnership cover matthew harrison
need deliv highli compel efficaci justifi car-t potenti cost usag
complex although car-t therapi shown robust durabl respons
test indic also limit toxic manufactur complex
reimburs challeng end compani develop newer
gener antibodi differ modal includ antibody-drug conjug
adc bispecif antibodi tend less toxic requir
gsk belantamab mafodotin could first bcma agent market r/r
mm dec gsk announc file belantamab mefadotin mg/kg r/r
mm base show orr median month
mg/kg dose file show orr median month
phase karmma data better expect high dose
cell achiev median month better
expect month hand orr cr
lower phase result orr cr in-lin
expect higher patient karmma vs phase refractori
agent darzalex could factor bristol expect file
base karmma high dose data comparison
car-t trial preliminari data show orr cr
similar safeti profil compar median follow-up six
month state primari complet sept
safeti profil look compar competitor car-t wors
bispecif t-cell engag rate grade neurotox
 cover matthew harrison
none/non gsk belantamab mafodotin notabl karmma
experienc one death due
move earlier line treatment challeng critic success
crowd market given hyper-competit environ bcma product
develop car-t agent could disadvantag rel bispecif
antibodi would consider easier administ potenti better
safeti ne observ could off-set lower
efficaci earli data competitor discuss previous bristol
see discuss demonstr high orr
compar await long-term follow-up data addit patient
understand durabl competitor therapi expect data
releas throughout gsk program aim
move respect bcma agent earlier treatment line gsk cover mark
median rang follow-up
prior therapi median
pt refratori ab
trae pt
grade grade
death due
ne grade grade
submit
data nejm data blood cancer journal data intern myeloma workshop
data
bcma bispecif t-cell engag multipl myeloma show compel
earli efficaci high infect rate dose treatment achiev
orr cr rate grade
infect four death includ one relat
due studi continu determin recommend phase dose notabl
bristol econom versu
bispecif antibodi would easier manufactur dose patient
said bristol develop varieti bcma modal includ car-t
bispecif t-cell engag
earli safeti efficaci data encourag long-term data need
bristol bcma car-t current phase evolv data
last present achiev orr good partial
respons vgpr better rate percent patient grade cytokin
releas syndrom neurotox grade await addit
patient data longer follow-up see differenti evolv
trial primari studi complet bristol
base case ep price-to-earnings multipl discount target
group averag bottom end group rang
believ multipl warrant near-term growth
accret balanc long-term uncertainti steepest patent
cliff mid-lat among peer
bull case ep
bull case ep
posit pipelin newsflow upsid financi surpris opdivo checkmate-
surprisingli match merck keytruda respect
result adjuv trial pipelin candid deliv clinic trial result
exceed expect revenu synergi upsid drive ep
engag value-enhanc strateg action
base case ep
base case ep
near-term accret growth balanc long-term uncertainti
assum opdivo result meet high bar set merck
keytruda deliv compel result ozanimod ibd result
bear case ep
bear case ep
pipelin financi fall short opdivo result
similar better merger integr problemat
synergi disappoint downsid revenu synergi yield ep
forecast
near-term growth rel inexpens
stock valuat key franchis set
compound-annual-growth-rate ep compound-annual-growth-rate
estim revenu
subject generic/biosimilar risk
bristol need add futur growth driver via
intern extern transact
higher/low model
quarterli result financi guidanc
result regulatori approv
psoriasi ozanimod ibd reblozyl md
car-t product
opdivo yervoy sale trend clinic
readout
immuno-oncolog news flow
competitor azn roch
extern busi develop
risk achiev price
upsid risk financi result
newsflow competitor disappoint
downsid risk financi shortfal
expect patent cliff disappoint
base case ep premium target
peer averag due lilli better growth prospect ep
bull case ep
bull case ep
earn forecast alzheim surpris upsid growth
driver upsid yield ep forecast alzheim surpris
upsid investor enthusiasm blockbust potenti step higher
base case ep
base case ep
upward pressur long-term consensu forecast pipelin progress drive
out-performance see potenti upward pressur consensu ep
due margin upsid posit pipelin progress also contribut modest
bear case ep
bear case ep
financi key pipelin agent disappoint us revenu growth miss due
competit pressur diabet autoimmun diseas drive earn
expect major clinic trial readout disappoint occur investor
becom concern us drug price risk
overweight share base upon
expect upward pressur long-
term consensu ep pipelin potenti
ep compar con revenue
ep
lilli offer higher durabl
growth prospect peer given
potenti margin expans pipelin
transact enhanc long-term growth
quarterli result financi guidanc
trulic jardianc taltz verzenio
extern busi develop
risk achiev price
upsid risk financi result
compet product disappoint
downsid risk financi result fall
short expect face us
compet drug surpris upsid
base case ep target multipl slight premium
target peer averag believ justifi given
strong growth prospect potenti upsid surpris
bull case ep
bull case ep
merck deliv sale margin expans upsid keytruda adjuv trial
succeed earli merck execut compel ep forecast
due higher-than-project keytruda sale drive oper leverag
base case ep
base case ep
merck deliv keytruda sale expect competitor lung
cancer trial match keytruda competitor lung cancer trial result
less inspir keytruda keytruda adjuv trial offer option
next year
bear case ep
bear case ep
keytruda gardasil disappoint drive ep forecast
competitor io trial show surprisingli strong result rel keytruda
overweight merck base upon
compel long-term growth prospect
see upsid lt consensu driven
oncolog franchis gardasil cancer
pipelin option diseas beyond
oncolog come focu come
keytruda sale trend trial
immuno-oncolog news flow
extern busi develop
us ex-u price develop
competitor dataset newsflow
risk achiev price
upsid risk financi upsid clinic
shortfal compel strateg action
downsid risk financi shortfal key
disappoint drug price pressur
base case ep target multipl slight discount
target peer averag believ warrant due
yr compound-annual-growth-rate revenu ep growth in-lin peer group
bull case ep
bull case ep
pipelin newsflow surprisingli encourag earn higher
anticip strateg action creat valu late-stag pipelin readout
compel ep forecast driven new product sale upsid
base case ep
base case ep
anticip improv growth driven new product fade gener
pressur assum prevnar infant data encourag
ibranc adjuv phase succe end modest neg impact
prevnar acip updat guidelin
bear case ep
bear case ep
shortfal occur pipelin disappoint us govern price
pressur wors expect product revenu face competit
data disappoint ibranc adjuv palla trial fail end
price-to-earnings contract due financi pressur pipelin failur price
equal-weight share although
anticip solid growth prospect see
stock fairli valu
revenu growth ep growth
pipelin execut key investor
given financi complex could
upward/downward surpris associ
financi result guidanc rel
ibranc growth driver perform
guidanc financi result
valent phase poc infant
 day march
polit action us drug price
risk achiev price
upsid risk core busi upsid
action creat sharehold valu
multipl expand due improv growth
downsid risk financi shortfal price-to-earnings
contract due pipelin shortfal strateg
action disappoint litig problem
neg us drug price develop
